As­traZeneca signs pre­clin­i­cal EGFR drug deal with an­ti­body biotech

With $45 mil­lion in up­front and near-term pay­ments, As­traZeneca is work­ing to ex­pand its EGFR pipeline through a deal with Pine­tree Ther­a­peu­tics for a pre­clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER